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This study aimed to determine the population pharmacokinetic (Pop PK) parameters
of cefazolin administered prophylactically at 25 mg/kg intravenously (IV) 30 min before
surgery in a canine population of 78 dogs and assess whether covariates, such as
sex, age, body weight (BW), breed, health status, creatinine level, and surgery time,
have an influence on cefazolin disposition. The ultimate goal was to compute PK/PD
cut off values and subsequently establish a specific clinical breakpoint (CBP) for the
development of an antimicrobial susceptibility test (AST) of cefazolin in dogs according
to the VetCAST approach. Two to 11 blood samples were collected from each dog from
5 to 480 min after cefazolin administration. A two-compartment model was selected,
and parameterization was in terms of serum clearance (CL), intercompartmental
CL(s) (Q) and volume(s) of distribution (V). The percentage of cefazolin binding to
serum protein was 36.2 ± 5.3%. Population primary parameter estimates V1, V2,
CL, and Q were (typical value ± SE) 0.116 ± 0.013 L/kg, 0.177 ± 0.011 L/kg,
0.0037 ± 0.0002 L/kg/min, and 0.0103 ± 0.0013 L/kg/min, respectively. Cefazolin
presented rapid distribution and elimination half-lives (mean ± SE) 4.17 ± 0.77 min
and 57.93 ± 3.11 min, respectively. The overall between-subject variability (BSV) for
estimated primary parameters ranged from 36 to 42%, and none of the seven explored
covariates were able to reduce this variability by an amplitude clinically relevant. By
Monte Carlo simulation, the probability of a PK/PD target attainment (here to achieve
a free serum concentration exceeding the MIC for 50% of the dosing interval in 90%
of dogs) was computed with a dosage of 25 mg/kg administered IV every 6 h for 4
administrations in 24 h. The computed PK/PD cut off value was 2 mg/L. In conclusion,
cefazolin administered prophylactically in surgical dogs at 25 mg/kg IV every 6 h was
deemed effective against pathogens with a MIC value ≤ 2 mg/L and from a PK/PD
perspective, can be recommended in a wide range of canine patient populations with
no necessary dose adjustment for special dog subpopulations.
Keywords: cefazolin, dog, prophylactic administration, surgery, population pharmacokinetics, PK/PD cut off
value
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INTRODUCTION
In animals as well as in human medicine, surgical site infection
(SSI) represents a dangerous complication that can easily lead
to an extension of hospital stay and an increase in medical
costs (Whittem et al., 1999; Hauser et al., 2006; Xu et al.,
2015). The perioperative administration of antimicrobial drugs
(AMDs) can decrease the incidence of SSIs (Brown et al.,
1997; Prospero et al., 2011; Xu et al., 2015); however, to avoid
serious consequences, such as the risk of hospital-acquired
infection and the selection of antimicrobial-resistant bacterial
strains, administration has to be carried out carefully and
appropriately (Song and Glenny, 1998; Knights et al., 2012). In
veterinary surgery, depending on the surgery site, pathogens,
such as Staphylococcus spp, Streptococcus spp, Enterobacteriaceae
and Pasteurella, are commonly encountered (Boothe and
Boothe, 2015). Cefazolin is a first-generation cephalosporin with
good activity against gram-positive cocci (Staphylococcus spp,
including beta-lactamase-producing strains, and Streptococcus
spp), many Enterobacteriaceae (E. coli, Klebsiella spp., Proteus
mirabilis), Pasteurella spp and anaerobes (Papich and Riviere,
2009). Thus, cefazolin has become one of the most commonly
AMD used perioperatively, and it has been recommended as the
ideal prophylactic AMD for dogs undergoing surgery based on
its spectrum, low toxicity and cost (Rosin et al., 1993; Marcellin-
Little et al., 1996; Gonzalez et al., 2017). Cephalosporins like
all beta-lactams have time-dependent killing activity; therefore,
antibiotic plasma concentrations should be kept above the
minimum inhibitory concentration (MIC) as long as possible
during therapy. This index is defined as T > MIC, and it has
been established that a T > MIC of 40–50% of the dosing
interval is adequate for a successful outcome. More precisely, as
only unbound drug concentration is available for antimicrobial
activity, the index should be measured as the duration of
free plasma concentration exceeding the MIC and is reported
as f T > MIC (Turnidge, 1998; Toutain et al., 2002; Papich,
2014). Recently for cefazolin, a breakpoint of efficacy against
bacteria isolated from animals was set at ≤ 2 mg/L (Papich,
2014; Clinical Laboratory Standards Institute [CLSI], 2015).
Cefazolin pharmacokinetics (PK) has been extensively studied
in dogs with a classical approach (Richardson et al., 1992;
Rosin et al., 1993; Petersen and Rosin, 1995; Marcellin-Little
et al., 1996; Singh et al., 1998; Harika et al., 2001; Gonzalez
et al., 2017). Following this, it has been recommended that
time-dependent AMD should be readministered every 2 half-
lives during surgery to maintain targeted plasma concentrations
(Marcellin-Little et al., 1996; Plumb, 2011; Gonzalez et al.,
2017).
Population pharmacokinetics (Pop PK) is widely applied to
define the sources of PK variability in target patient populations,
thus identifying and assessing demographic, pathophysiological,
environmental, and drug-related factors that can influence
drug disposition (Ette and Williams, 2004; Kiang et al., 2012).
Population modeling is also used in clinical trials, where the
participants are representative of the real treated population,
in contrast to healthy subjects or highly selected patients in
traditional PK studies (Riviere, 2009; Bon et al., 2017). Moreover,
through a Pop PK approach with a sufficient knowledge of
covariates, it is possible to predict a typical PK profile for any
given patient, allowing the definition of the correctness of the
treatment (Concordet et al., 2004). In veterinary medicine, over
the last decades, many Pop PK studies regarding AMDs have
been performed in dogs (Regnier et al., 2003; Zhao et al., 2012;
Prados et al., 2014; Hnot et al., 2015; Papich, 2017), but no
study has been carried out with cefazolin. Starting from these
assumptions, the aim of the study was to determine the Pop PK
profile of cefazolin administered prophylactically at 25 mg/kg by
intravenous (IV) bolus 30 min before surgery in a representative
canine population to identify whether covariates such as sex,
age, body weight (BW), breed, health status, creatinine level
and surgery time, have an influence on cefazolin disposition.
Furthermore, the ultimate goal was to compute PK/PD cut off
values to establish a specific clinical breakpoint (CBP) for the
development of an antimicrobial susceptibility test (AST) of
cefazolin in dogs, according to the VetCAST approach (Toutain
et al., 2017).
MATERIALS AND METHODS
Animals
With ethical approval (Organismo Preposto al Benessere
Animale, OPBA_23_2016) and after obtaining the owners’
written consent, 78 client-owned dogs were enrolled for
the study. Dogs were of different breeds, sexes, ages,
BWs and healthy or presenting concomitant diseases, all
scheduled at the University Veterinary Hospital of Milan
for any type of surgical procedure. In all subjects, type of
surgery, duration of the procedure, anesthetic and analgesic
perioperative protocol and medical history were recorded.
For each dog, the blood count and biochemical profile were
evaluated.
Sample Collection and Analysis
Before drugs administration, 1 mL of venous blood was
collected through an angio-venous catheter (Surflo R©, 20 G,
32 mm IV catheter Terumo, Vetefarma Srl, Cuneo, Italy)
previously placed into a peripheral vein. For surgery, each
dog was premedicated, generally with sedatives (i.e., α2-
agonists) and opioids (i.e., methadone) and put under general
anesthesia, induced by propofol and maintained with isoflurane
in 100% oxygen. Thirty min after the surgical procedures,
meloxicam (0.2 mg/kg, Metacam, Boehringer Italia, Milan,
Italy) was administered subcutaneously as an analgesic drug.
Cefazolin (Cefazolina Teva, Teva Italia S.r.l., Milan, Italy) was
administered via IV bolus to all dogs at 25 mg/kg 30 min before
surgery. For cefazolin quantification, venous blood samples
(1 mL each) were collected from each subject at prefixed
times (5, 10, 15, 30, 45, 60, 90, 120, 150, 180, 240, 360,
and 480 min). Then, all samples were centrifuged (4000 g,
10 min) to obtain serum and frozen at −20◦C pending
analysis.
Cefazolin was extracted and quantified by HPLC-UV from
canine serum samples according to the published method
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by Kunicki and Was (2012) with slight modifications (see
Supplementary File S1 for details). The analytical method was
validated in our hands in compliance with the recommendations
defined by the European Community (European Commission,
2002; Commission decision 2002/657/EC) and with the
international guidelines (European Medicine Agency [EMA],
2011 – VICH GL49). The calibration curves were prepared
with 6 spiked solutions obtained diluting the original stock
solution of cefazolin (1 mg/mL) in canine blank serum to
achieve concentrations ranging from 0.2 to 20 µg/mL. The
correlation coefficients (r) resulted > 0.99 for 2 replicates.
The precision (repeatability) and accuracy were determined
by analyzing blank samples (n = 6 for each concentration)
that were spiked with 0.2, 2, or 20 µg/mL of cefazolin. The
results fell within the accepted ranges for precision (6.75,
13.9, and 13.5% for 0.2 µg/mL, 2 µg/mL, and 20 µg/mL,
respectively) and accuracy (2.5,−3.42, and 2.66% for 0.2 µg/mL,
2 µg/mL and 20 µg/mL, respectively). A LOQ value of
0.2 µg/mL was set. The LOD was 0.00024 µg/mL. The
specificity of the method was demonstrated by the absence
of interference in 20 blank serum samples at the cefazolin
retention time. In the case of samples above the upper limit of
quantification (20 µg/mL), these samples were quantified upon
dilution.
The percentage of cefazolin serum protein binding was
determined in vitro with ultrafiltration units (Amicon
Ultrafree MC-0.5 mL, Centrifugal Filter Unit 30 K, Merck
Millipore, Milan, Italy) according to Villa et al. (1997).
Spiked blood samples with cefazolin concentrations from
5 to 100 µg/mL were incubated for 30 min at 37◦C before
ultrafiltration. Subsequently, the sera were centrifuged
(5000 g, 20 min) with 30000 Nominal Molecular Weight
Limit (NMWL) cut-off ultrafiltration units and injected into
a HPLC system. The binding percentage was calculated by
serum (unbinding drug) and water (total cefazolin) peak area
ratio.
Population Pharmacokinetics and Monte
Carlo Simulation
Pharmacokinetic modeling was carried out using commercially
available software (Phoenix NLME version 7.0, Certara, St.
Louis, MO, United States). A nonlinear mixed effects (NLME)
approach was used to generate Pop PK parameter estimates. Two-
and three-compartment models were evaluated to identify the
model that best described the dataset. After visual inspection
of plots for all dogs showing a polyphasic decay of plasma
concentration vs. time, data were fitted with a two or
three-compartment models. The two concurrent models were
then compared using the likelihood ratio test (LRT) that is
appropriate when models are nested (one model is a subset
of another) and have different numbers of parameters. The
critical value of the χ2 distribution to consider was obtained
using Excel (Microsoft Office 2016) to estimate the risk of
type one. Finally, a two-compartmental model was selected.
Parameterization was in terms of serum clearance (CL),
intercompartmental CL(s) (Q) and volume(s) of distribution
(V) with V1, V2, CL, and Q being the primary estimated
parameters. The following parameters were computed as
secondary parameters.
The terminal slope Beta was obtained with Eq. 1;
Beta = 0.5 ×
[
Q
V1
+ Q
V2
+ CL
V1
−
[(
Q
V1
+ Q
V2
+ CL
V1
)2
− 4 Q
V2
× CL
V1
]0.5]
The initial slope of distribution, Alpha, was obtained with
Eq. 2; Alpha = QV2 × CLV1/Beta and the elimination (HLBeta) and
distribution (HLAlpha) half-lives were obtained with classical
equations. The area under the curve (AUC), the steady-state
volume of distribution (Vss) and the volume of distribution
associated with the terminal phase (Vz) were also computed as
secondary parameters with classical equations.
The between-subject variability (BSV) was modeled using an
exponential model (Eq. 3), and hence the CL for the ith subject
was written as:
Cli = θmedian × Exp(ηi)
where Cli is the CL in the ith animal, θmedian is the population
median CL (typical value of CL) and ηi the deviation (noted
ETA) associated with the ith animal from the corresponding
θmedian population value. Others individual parameters (i.e., V1,
V2, and Q) were modeled using equations of the same form. The
distribution of the ETAs was assumed to be normal with a mean
of 0 and a variance (ω2x). In addition, the individual parameters
and consequently their corresponding ETAs can be correlated.
All these correlations were estimated and the corresponding
covariances were stored in the variance-covariance omega ()
matrix. The following equation 4 was used to convert the variance
(ω2clearance) of the log-transformed CLs into a coefficient of
variation (CV %) in the original scale:
CVclearance(%) = 100×
√
exp(ω2clearance)− 1
The shrinkage of random effects toward the means was calculated
for the ETAs (Karlsson and Savic, 2007) with equation 5:
Shrinkage = 1− SD(EBEη)
ω
where ω is the estimated variability for the population and SD
is the standard deviation (SD) of the individual values of the
empirical Bayesian estimates (EBE) of η.
The residual model was an additive plus a multiplicative
(proportional) model of the form (Eq. 6):
C(t) = f (θ,Time)× (1+ ε1)+ ε2
with ε1 and ε2, the multiplicative and additive error terms having
a mean of 0 and a variance noted σ1 or σ2, respectively. In
Phoenix, when this error model is used, the additive sigma
is reported as its SD, noted stdev, with the same units as
serum concentration (µg/mL) and the multiplicative sigma is
called multStdev and the 100∗ multStdev is the corresponding
coefficient of variation.
Parameter estimation was based on minimizing an objective
function value (OFV), using maximum likelihood estimation
(i.e., minus twice the log of the likelihood) given for each model.
The first order conditional estimation extended least squares
Frontiers in Pharmacology | www.frontiersin.org 3 October 2018 | Volume 9 | Article 1137
fphar-09-01137 October 5, 2018 Time: 19:9 # 4
Cagnardi et al. Population Pharmacokinetics of Cefazolin in Dogs
(FOCE ELS) engine was used for analyses approximating the
marginal likelihood while searching for the maximum likelihood.
There was no censored data. A bootstrap approach was used to
estimate typical values of parameters and precision of estimates
that are reported as SE, CV % and by their 95% confidence
intervals. To evaluate the overall performance of the final model,
a visual predictive check (VPC) was plotted to compare actual
observations with simulated replicates from the model (500
replicates per investigated dogs). The 90% prediction intervals
were constructed and plotted together with the observed data
allowing for a visual assessment of the agreement between
simulation and observation. Diagnostic plots, the distribution of
errors, and the precision of the parameter estimates were used as
tools to evaluate the goodness of fit and to compare models.
The LRT was used to examine different models for testing the
residual variability and the covariate effect on each PK parameter.
An analysis of each covariate in all PK parameter was carried
out to evaluate the significance on the model. The categorical
covariates considered were the health status with two levels
(healthy, diseased), the sex with three levels (male, female, and
female neutered) and the breed with two levels (mongrel and
other breeds) (Eq. 7):
Param = θmedian × (1+ θ1X1)
where Param is one of the structural parameter of the disposition
model (V1, V2, CL, Q), X1 is an indicator variable with a value
of 0 for control condition (the healthy condition for the health
status, mongrel dog for breed), and of 1 for the non-mongrel
breed and disease status. For example for V1, the model was given
either by Eq. 8 for the healthy condition, or Eq. 9 for the diseased
condition:
V1 = θV1median × EXP(ηV1)
V1 = θV1median × (1+ θ1)× EXP(ηV1)
where θv1median is the typical value of V1, ηV1 is the ETAs
associated with V1 and θ1,the fixed effect of the covariate for
the diseased condition. If θ1 is significantly different from 0, it
provides evidence that a difference exists between the healthy
status and the disease condition for V1.
Age, BW, creatinine level and surgery time were considered
as continuous covariates and their influence were modeled using
a classical regression equation with a power model and an
appropriate scaling factor for each covariate; for example serum
CL was modeled with the following general equation 10:
CL = θ1 ×
[
Age
8
]θ2
×
[
BW
20
]θ3
×
[
CREAT
0.9
]θ4
×
[
Surgery_time
80
]θ4
where θ1 is the typical value of CL for a 8 years old dog, weighting
20 kg, having a creatinine level of 0.9 mg/dL and for a surgery
time of 80 min. The stepwise covariate search mode was used
to define the statistically significant covariates for each of the
structural parameters of the model. This run mode performs a
stepwise forward or backward addition or deletion of covariates
effects (by adding one at a time) to determine the improvement
of the final model based on the Bayesian information criterion
(BIC). For the present analysis, we selected a BIC value of
6.635 for adding a covariate and a value of 10.823 for deleting
a covariate, as these values are equivalent of P < 0.01 and
P < 0.001 for the minus twice the log-likelihood (2-LL) criterion
when using the LRT test (see Supplementary File S2 for further
details).
Using the previously developed Pop PK model and estimated
parameters, 2500 curves of the cefazolin disposition were
generated by the Monte Carlo simulation. The simulated dosage
regimen was of 25 mg/kg IV at 6 h intervals over 24 h (i.e.,
four administrations of cefazolin at 0, 360, 720, and 1080 min).
The 2500 curves were analyzed with the non-compartmental tool
of Phoenix. The duration for which free plasma concentrations
were above the selected MICs (from 0.25 to 8 mg/L) was
computed using the statistical tool of Phoenix. The quantiles 90
and 95% of the distributions of these different times above MIC
were computed to give the corresponding probability of target
attainment (PTA) of the selected index (f T > MIC for 50% of
the dosing interval). The PTAs were computed without their
confidence intervals.
RESULTS
Animals and Cefazolin Concentrations
Seventy-eight dogs were enrolled in the study; animal
characteristics are reported in Table 1 together with the
covariates and coding used for Pop PK modeling. Most dogs had
some conditions and were undergoing different types of surgery
from oncologic to ophthalmic; only 19 dogs were healthy and
undergoing gynecological or andrological surgery. The dogs of
the study represented many different breeds (n = 26), from Jack
Russell Terriers to Pyrenean Sheepdog; among these, 12 breeds
were represented by more than 1 dog and 14 were represented by
only one dog.
Two to 11 (median 9) blood samples were collected from
each dog from 5 to 480 min for 14 different sampling
times for a total of 629 collected samples. Cefazolin serum
concentrations obtained in all animals are reported in Figure 1
and a biexponential decay over time is shown. The percentage
of cefazolin binding to serum protein, calculated with the
ultrafiltration method, resulted in 36.2± 5.3%.
Population Pharmacokinetics and Monte
Carlo Simulation
The two-compartment model was adequate to describe cefazolin
disposition in our dogs, as shown in the VPC plot (Figure 2)
and in the plots of the observed cefazolin concentration versus
population predicted concentration (PRED) or versus individual
predicted concentration (IPRED) (Figures 3A–D). The model
adequacy was further supported by the inspection of different
goodness-of-fit plots (see Supplementary Figures S1—S4).
Typical values of the primary structural parameters of the
model, secondary parameters, their associated standard error
(SE) and the SD of the residual for the basic model are given in
Table 2.
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TABLE 1 | Animal characteristics, covariates and coding used in Pop PK analysis.
Mean ± S.D. Range (median)
Continuous covariates
Age (y) 7.22 ± 4.11 0.66–14 (8)
Body weight (kg) 26.13 ± 0.88 4.5–56 (27)
Creatinine level (mg/dL) 0.91 ± 0.32 0.3–1.88 (0.9)
Surgery Time (min) 87.63 ± 58.09 20–260 (80)
Type and number of subjects (Code)
Categorical covariates
Health status Healthy n = 19 (Code 0) Diseased n = 59 (Code 1)
Breed Mongrel n = 27 (Code 0) Other breeds n = 51 (Code 1)
Sex Male n = 32 (Code 0) Female n = 23 (Code 1) Female neutered n = 23 (Code 2)
FIGURE 1 | Semi-logarithmic spaghetti plots of the disposition curves of
cefazolin over 480 min after a single IV bolus administration (25 mg/kg) in
78 dogs.
For BSV, an exponential model was selected, because
the estimated thetas parameters must be positive and their
distribution is generally right-skewed. The estimates of the
random effects variance-covariance matrix, correlation matrix
and shrinkage are reported in Table 3. The full variance-
covariance omega () matrix was selected, because in a mixed
effect model, inclusion of covariance terms prevented the risk of
biased estimation of the variance terms (the diagonal). It also
allowed for checking possible correlations between the ETAs
that would suggest some over parameterization of the model
(statistical collinearity). Inspection of Table 3 showed no spurious
correlation between ETA and low values for ETA shrinkage
indicating that data were rich enough to properly estimate the
random component of the model.
The bootstrap estimate of the BSV for the 4 primary
parameters and precision of their estimate (expressed as CV%)
were also calculated and are reported in Table 4. Inspection
of Table 4 indicates that bootstrap estimates of the BSV were
consistent with those obtained by a single run of all the data
set (Table 3) and that the precision of the BSV estimates were
robust (low CV%). The BSV for CL (the parameter controlling
the overall cefazolin exposure) was rather high (CV = 36.83%)
and prompted us to explore the influence of different clinically
relevant covariates to explain the variability in the observed, large
clinical population.
The significant influence of each covariate (sex, age, breed,
BW, health status, creatinine level, and surgery time) on the
model was explored with a stepwise covariate search mode.
The diseased condition was defined based on clinical exam,
anamnesis and hematological and biochemical blood tests. As
cefazolin is mainly excreted by the kidney (approximately 80%,
Nishida et al., 1970) the creatinine levels was used as a covariate
to assess individual kidney conditions. Continuous covariates
were scaled to avoid instability of the optimization process
and to provide parameter estimates that were more reflective
of the average subject; the scaling values were BW = 20 kg,
age = 8 years, creatinine level = 0.9 mg/dL and surgery
time = 80 min. The scatter plot matrix for the continuous
covariates (age, BW, creatinine level, and surgery time) is
reported in Supplementary Figure S5. The visual inspection
of the figure shows no obvious relationship, but there was a
trend between creatinine level and age and BW. The scatter plot
matrices for the continuous covariates (age, BW, creatinine level,
and surgery time) per health status level (0= healthy, 1= disease)
are reported in Supplementary Figures S6A,B. Moreover, in
this case, the visual inspection of the figure shows no obvious
relationship.
The Phoenix stepwise search exploratory tool returned 27
combinations (scenarios) of covariates, ensuring a statistically
significant (P < 0.01) reduction of the BIC criterion. The
most significant scenarios were those related to V1 and for 16
scenarios that included two covariates, the BW was selected
as the covariate. Among these scenarios, the most relevant
to perform subsequent simple runs were chosen and fitted to
estimate the magnitude of the effect. Finally, to assess whether
these statistically significant covariates had clinical relevance and
merit for future recommendation or warning, the influence of
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FIGURE 2 | Visual Predictive Check (VPC) plot obtained with 500 replicates of each animal (314500 simulated data). Red lines: observed quantiles; Black lines:
predicted quantiles; Black circles: observed data. The shaded areas represent the 90% confidence intervals around the 10th, 50th, and 90th percentiles of the
simulated data.
covariates on PK parameters (V1, V2, CL, Q) was explored by
computing the multiplicative/dividing factor when the covariate
increased or decreased by 50%.
For example for BW as a covariate, we computed the values
of PK parameters for a typical dog of 20 kg BW (see equation
10). When only the BW influenced the CL, the typical value of
the fixed effect (θ2in equation 10) was of -0.2368. This means
that for dogs of 10 and 30 kg BW, i.e., for dogs having a BW of
plus or minus 50% of the scaled typical value, the typical value
of CL was increased of time folds a factor of 1.178 for a dog of
10 kg BW and was multiplied by 0.908 in a dog of 30 kg BW (or
equivalently divided by 1.10). Such a difference can be considered
as not relevant from a clinical point of view (see Supplementary
File S2 for further details).
For age, BW, creatinine level and surgery time, the influence
was not clinically relevant. For the health status, all PK
parameters were influenced, but the largest effect was observed
for the Q (-0.267), meaning that in diseased dogs, the
intercompartmental CL that likely reflects tissular blood flow, was
decreased by 26.7% compared with that in control dogs. Other
influences of disease were clinically irrelevant. For breed and sex,
the magnitude of the effects was also clinically irrelevant despite
their statistical significance. It has to be said that, statistical
significance does not always mean clinical relevance, as especially
in this trial where rich and robust data were analyzed, allowing
to easily detect statistically significant differences but having no
clinical impact.
By Monte Carlo simulation, 2500 curves were generated using
this Pop PK model to compute the PTA corresponding to the
selected possible MIC in order to propose a PK/PD cutoff,
considering the average percentage of unbound drug calculated
(i.e., 0.64; percentage of cefazolin binding 36 ± 0.53%). Table 5
reports the results of f T > MIC for the 2500 curves simulated
for a dosing regimen of 25 mg/kg at 6 h interval over 24 h. In
Table 5 it is shown that for a MIC of 2 mg/L (i.e., a total serum
concentration of 3.12 mg/L, corrected for the unbound fraction
of the drug), 90% of dogs had a f T>MIC of 57% over the dosage
interval (24 h). Thus, the PK/PD cutoff for a f T > MIC target of
50% of the dosage interval and a 90% quantile (or 95%) is set at
2 mg/L.
DISCUSSION
Cefazolin is very commonly used perioperatively and has been
recommended as an appropriate prophylactic antimicrobial for
dogs undergoing surgery. Currently, its use is based on not
recent studies with classical PK investigation that do not consider
the possible large inter-animal variability encountered in clinical
practice nor the most recent PK/PD paradigms allowing to
support the prudent use of the AMD at a population level. Thus,
by developing a Pop PK model, the aim of this study was to
estimate typical PK parameters of cefazolin, their BSVs and to
identify whether covariates such as sex, age, BW, breed, health
status, creatinine level, and surgery time, have an influence on
these parameters and in turn, to explain the BSV of cefazolin
disposition. Moreover, to promote a responsible use of cefazolin
in dogs, the study aimed to compute a PK/PD cutoff value for the
subsequent determination of a specific CBP for the development
of an AST, using the VetCAST approach (Toutain et al., 2017).
A large number of dogs were enrolled in the study
(n = 78) with variable characteristics reflecting the target clinical
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FIGURE 3 | Plots of the observed cefazolin concentration (µg/mL) versus population predicted concentration (PRED; µg/mL – A in logarithmic scale; B in arithmetic
scale) and versus individual predicted concentration (IPRED; µg/mL – C in logarithmic scale; D in arithmetic scale).
population of dogs undergoing surgery. Only 19 dogs were
healthy, and among the diseased dogs, 60% were oncologic
patients. Many different breeds were represented in the study
together with a large number of mongrels, accounting for
the wide variability encountered in clinical practice. Many
blood samples were taken from each animal; thus, the large
availability of data (n = 629 samples) made its analysis reliable,
especially for the estimation of the BSV that require a minimal
number of samples per animal to avoid an ETA-shrinkage, i.e.,
the individual parameter estimates “shrink” back toward the
population parameter estimate (Karlsson and Savic, 2007). In
the present trial, all ETA-shrinkages were rather low giving
confidence in the value of the individual EBE (individual ETA)
and post hoc computations.
After cefazolin administration, a biexponential decay was
observed in our samples, as also reported by other authors
(Rosin et al., 1993; Marcellin-Little et al., 1996; Singh et al., 1998;
Harika et al., 2001), and the two-compartment model was the
most adequate to describe cefazolin disposition in dogs. The
percentage of cefazolin binding to protein was 36.2 ± 5.3%.
This value was in agreement with a previous study reporting
38.8 ± 2.51% from a bioassay and 35.8 ± 2.64% from isotopic
methods (Daly et al., 1982).
The primary and secondary Pop PK estimates were in
agreement with the results obtained with classical PK modeling
reported by other authors, although all were obtained with
different analytical techniques (microbiological assay vs. HPLC)
or with different doses (Rosin et al., 1993; Marcellin-Little et al.,
1996; Singh et al., 1998; Harika et al., 2001). For example,
elimination half-life was (typical value ± SE) 57.93 ± 3.11 min
in our study vs. 55.08 ± 7.92 min (mean ± SD) in the study
by Rosin et al. (1993) or 52.3 min by Marcellin-Little et al.
(1996) when administered via IV at 20 or 22 mg/kg, respectively.
In contrast, only a population investigation allows for proper
estimation of a BSV reflecting altogether the main sources of
variability encountered in all-coming dogs. For example, the
BSV as it can be roughly estimated from the mean and SD
reported by Rosin et al. (1993) is of approximately 14.4%,
while from our 78 dogs, considering the post hoc estimates
of individuals ETAs and solving equation 1 to compute the
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TABLE 2 | Population primary and secondary parameters of cefazolin in dogs obtained with a two-compartment model (bootstrap estimates of mean, median, SE,
CV%, 2.5%, and 97.5% percentiles).
Parameters Units Mean SE CV% Median 2.5% 97.5%
Population primary parameters
tvV1 L/kg 0.116 0.013 11.36 0.115 0.084 0.137
tvV2 L/kg 0.177 0.011 6.01 0.176 0.158 0.194
tvCL L/kg/min 0.0037 0.0002 4.26 0.0036 0.0034 0.0040
tvQ L/kg/min 0.0103 0.0013 12.82 0.0105 0.0073 0.0123
tvCMultStdev 0.257 0.016 6.08 0.256 0.226 0.285
stdev (sigma) µg/mL 0.564 0.166 29.42 0.543 0.314 0.943
Secondary parameters
AUC µg∗min/mL 6790 286 4.21 6810 6189 7391
Beta 1/min 0.0111 0.0006 5.29 0.0111 0.0100 0.0122
Beta half-life min 57.93 3.11 5.38 57.72 52.45 63.84
Alpha 1/min 0.172 0.031 18.21 0.171 0.115 0.241
Alpha half-life min 4.17 0.77 18.45 4.06 2.88 6.04
Vss L/kg 0.292 0.013 4.33 0.293 0.266 0.316
MRT min 79.34 4.25 5.36 79.25 71.74 86.12
Vz L/kg 0.334 0.016 4.71 0.335 0.305 0.365
Typical values (tv); V1, volume of the central compartment; V2, volume of the peripheral compartment; CL, serum CL; Q, intercompartmental CL; CmultStdev, multiplicative
component of the residual that can be read as a coefficient of variation of 25.7%; stdev, standard deviation of the additive component of the residual; AUC, area under
the curve; Beta, slope of the terminal phase; Beta half-life, half-life of elimination; Alpha, slope of the distribution phase; Alpha half-life, half-life of distribution; MRT, mean
residence time; Vz, volume of distribution associated with the terminal phase; SE, standard error of estimate.
TABLE 3 | Estimates of the random effects variance-covariance matrix, correlation
matrix and shrinkage.
Omega
nV1 0.092598
nV2 0.099641 0.135063
nCL 0.031062 0.073881 0.130511
nQ 0.00518 0.062008 0.068201 0.196614
Correlations between ETAs and Shrinkage
nV1 1
nV2 0.89 1
nCL 0.28 0.56 1
nQ 0.04 0.38 0.43 1
Shrinkage 0.15 0.11 0.05 0.34
Variance (diagonal) is in bold. nV1, nV2, nCL and nQ are the random component
of the model (ETA). Corresponding BSV expressed as a CV% are 31.15, 38.03,
37.34, and 46.61% for nV1, nV2, nCl, and nQ, respectively (see equation 4).
TABLE 4 | The bootstrap estimates of the Between Subject Variability (BSV) for
the 4 primary parameters and precision of their estimate (expressed as CV%).
BSV (%) Precision (CV%)
nV1 31.42 24.00
nV2 42.70 22.34
nCL 36.83 12.80
nQ 46.12 26.48
nV1, nV2, nCL, and nQ are the random component of the model (ETA).
Corresponding BSV is expressed as a CV%, as well as precision of the estimate.
terminal half-life, its BSV was estimated at 31.2%. This point
should be highlighted when computing the PK/PD cut off to
establish a CBP for an AST using the VetCAST approach, because
TABLE 5 | Time (min) above possible MICs ranging from 0.25 to 8 mg/L
corresponding to total serum concentration ranging from 0.39 to 12.5 mg/L for the
quantiles (Q) 90 and 95% and corresponding value of the T > MIC in % of 24 h.
MIC
(mg/L)
Total serum
concentration
(MIC/unbound
fraction)
Time min
(Q90%)
T > MIC
(%)
Time min
(Q95%)
T > MIC
(%)
0.25 0.39 1345 93.4 1197 83.1
0.5 0.78 1169 81.2 1062 73.7
1 1.56 882 61.2 787 54.6
2 3.12 821 57.0 735 51.1
4 6.25 530 36.8 468 32.5
8 12.5 463 32.1 407 28.3
Q90%: quantile 90%; Q95%: quantile 95%; for a MIC of 2 mg/L corresponding to
a total serum concentration of 3.12 mg/L, 90% of the simulated curves were equal
or above a free plasma concentration for 821 min, i.e., for 57% of the considered
dosing interval.
AST should a priori cover most individuals within the targeted
population, not only a limited number of experimental dogs. We
were also in position to investigate the influence of the different
measured covariates. This is of relevance when establishing a
CBP, because the identification of a subpopulation could lead
to some specific comments to assist clinical microbiologists
in the routine interpretation of AST data and in suggesting
the most appropriate actions to be taken in response to AST
results. In addition, identification of a subpopulation could
lead to some specific recommendation in terms of dosing
regimen.
The influences of age, BW, creatinine level and surgery
time on the exposure of cefazolin were not clinically relevant.
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Health status statistically influenced all primary PK parameters,
with the most evident effect being on the decrease in the
intercompartmental CL in diseased dogs; nevertheless, this
influence can be considered too low a magnitude to be clinically
relevant. Overall, the Pop PK analysis performed showed that the
25 mg/kg dosage provides consistent cefazolin exposure in a wide
range of canine patients and no adjustment of dose for special dog
populations seems necessary.
Dosage recommendations for surgical prophylaxis
administration of cefazolin to dogs varied from 20 to 25 mg/kg
IV at beginning of surgery or 30 min before, followed by
20 mg/kg IV every 60 or 90 min until wound closure or
20 mg/kg SC at 6 h (Rosin et al., 1993; Whittem et al., 1999;
Plumb, 2011). The practice of frequent repetition of cefazolin
administration during surgery has been suggested to produce
very high serum concentrations (10 × MIC; i.e., 20 mg/L)
to prevent infection from skin contaminants (Marcellin-Little
et al., 1996). Nevertheless, for a time-dependent AMD, like
cefazolin, these very high concentrations may be unnecessary,
and a standard PK/PD target is to maintain plasma concentration
above the MIC90 of putative pathogens for a least 50% of a
dosing interval (Turnidge, 1998; Toutain et al., 2002; Papich,
2014). The bacteria most commonly involved in SSIs of dogs
are commensal organisms on the skin such as Staphylococcus
pseudintermedius, a gram-positive bacterium for which a CBP of
2 mg/L has been proposed by the Clinical Laboratory Standards
Institute (CLSI) for skin and soft tissue infections with a dosage
regimen of 25 mg/kg administered every 6 h (Clinical Laboratory
Standards Institute [CLSI], 2015). The present trial is consistent
with such a CBP. By using our population model and Monte
Carlo simulations, we established a PK/PD cut off of 2 mg/L for a
dosage of 25 mg/kg administered every 6 h (4 administration
in 24 h) and a target f T > MIC set at 50% of the dosing
interval to be achieved in at least 90% of a representative dog
population.
CONCLUSION
In conclusion, from a PK/PD perspective, the present
population investigation supports cefazolin use for empirical
prophylactic administration to dogs 30 min before surgery with
possible readministration at 6 h interval for pathogens with a
MIC ≤ 2 mg/L.
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